Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
|Videos|February 13, 2016
Dr. Matthew Cooperberg on the Effectiveness of Active Surveillance in Prostate Cancer
Author(s)Matthew Cooperberg, MD
Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.
Advertisement
Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco (UCSF), discusses the effectiveness of active surveillance in prostate cancer. Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.
Advertisement
Related to this article
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Oncologists discuss LITESPARK-011 findings and the potential role of belzutifan plus lenvatinib in second-line advanced renal cell carcinoma treatment and sequencing.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5